Online inquiry

IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8668MR)

This product GTTS-WQ8668MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM), AL amyloidosis research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ8668MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5326MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ2893MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ46MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ12887MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ5576MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP-771
GTTS-WQ13060MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ13388MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PR-1594804
GTTS-WQ2606MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 557
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW